There were no differences in treatment-related side effects between the 10-mg and 80-mg diabetic groups.
Treatment-related myalgia occurred in 3.6% of the 10-mg group and 2.4% of those taking 80 mg, while persistent liver-enzyme elevations three times the upper limit of normal occurred in 0.4% vs. 0.8%, respectively. No cases of rhabdomyolysis occurred in any patient throughout the 5 study years.